What is MediciNova, Inc. (MNOV) stock price today?

MediciNova, Inc. (MNOV) is currently trading at $1.52, down 1.3% today.

What is MNOV P/E ratio?

MediciNova, Inc.'s P/E ratio is -8.20. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is MNOV return on equity (ROE)?

MediciNova, Inc.'s return on equity (ROE) is -26.51%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is MediciNova, Inc.'s market cap?

MediciNova, Inc. has a market capitalization of $74.82M.

NASDAQ · Biotechnology

MediciNova, Inc. (MNOV) Stock

$1.52 -1.30% NASDAQ: MNOV Healthcare

Valuation

Metric	Value
Price	$1.52
Market Cap	$74.82M
P/E Ratio	-8.20
P/B Ratio	2.35
P/S Ratio	95.18
EPS (TTM)	$-0.24
52-Week High	$3.90
52-Week Low	$1.17
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-26.51%
ROA	-26.59%
ROCE	-31.62%
Gross Margin	15.20%
Operating Margin	-21.65%
Net Margin	-19.64%
Debt/Equity	0.00
Current Ratio	7.75

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$4.0M	$0	$1.0M	$0	$0
Operating Profit	$-10.0M	$-15.0M	$-10.0M	$-13.0M	$-13.0M
Net Profit	$-10.0M	$-14.0M	$-9.0M	$-11.0M	$-12.0M
EPS	$-0.21	$-0.29	$-0.17	$-0.23	$-0.24
Op Margin	-253.0%	—	-990.0%	—	-3242.5%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$87.0M	$74.0M	$66.0M	$56.0M	$46.0M
Total Liabilities	$4.0M	$4.0M	$4.0M	$3.0M	$4.0M
Cash	$71.0M	$19.0M	$51.0M	$40.0M	$31.0M
Borrowings	$1.0M	$1.0M	$0	$0	$0

Latest News

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients GlobeNewswire · Jul 15, 2026 MediciNova CEO Provides Shareholder Update GlobeNewswire · Jun 30, 2026 Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight GlobeNewswire · Jun 8, 2026 MediciNova Granted US Patent Notice of Allowance for Ibudilast Combination to Treat Brain Cancer MT Newswires · Jun 8, 2026 MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment GlobeNewswire · Jun 8, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-9.0M	$-13.0M	$-7.0M	$-11.0M	$-10.0M
Investing Cash Flow	$0	$-40.0M	$40.0M	$0	$0
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$11.0M	$-53.0M	$32.0M	$-11.0M	$-10.0M
Free Cash Flow	$-9.0M	$-13.0M	$-7.0M	$-11.0M	$-10.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.94
EV / EBITDA	-5.68
FCF Yield	-2199.71%
Quick Ratio	8.75
Interest Coverage	0.00
Return 1Y	10.60%
Return 3Y	-46.86%
Return 5Y	-64.11%

Ownership

Insiders Held2.88%

Institutions Held11.04%

Institutions Float Held11.36%

Institutional Holder	Shares	Report Date
Essex Woodlands Management Inc.	1,105,941	2026-03-31
Blackrock Inc.	705,954	2026-03-31
Citigroup Inc.	635,715	2026-03-31
Vanguard Capital Management LLC	611,039	2026-03-31
Geode Capital Management, LLC	543,843	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACRVAcrivon Therapeutics, Inc.	$1.91	+2.14%	-1.12	$81.75M	0.00%
BMEABiomea Fusion, Inc.	$1.42	+3.65%	-2.56	$102.67M	0.00%
CBUSCibus, Inc.	$1.55	-2.52%	-1.04	$118.31M	0.00%
FBIOFortress Biotech, Inc.	$2.13	+2.15%	0.64	$70.92M	0.00%
IMUXImmunic, Inc.	$8.19	+8.33%	-1.59	$111.56M	0.00%

About MediciNova, Inc.

MediciNova, Inc. is led by CEO Yuichi Iwaki, employs 13 people, headquartered in US, publicly traded since 2006.

MediciNova, Inc. (MNOV) stock trades at $1.52 with a market capitalization of $74.82M. The stock is valued at a price-to-earnings (P/E) ratio of -8.20, price-to-book of 2.35, price-to-sales of 95.18. Over the past 52 weeks the stock has ranged between $1.17 and $3.90, and currently trades 61.0% below its 52-week high.

On profitability, MediciNova, Inc. generates a return on equity (ROE) of -26.51%, return on capital employed of -31.62%, an operating margin of -21.65%, a net profit margin of -19.64%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides